Literature DB >> 7921210

Bone resorption in healthy and osteoporotic postmenopausal women: comparison markers for serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links.

M J Välimäki1, R Tähtelä, J D Jones, J M Peterson, B L Riggs.   

Abstract

We compared two highly specific markers for bone resorption-pyridinium cross-links (pyridinoline (PYR) and deoxypyridinoline (DPR)) in urine and carboxy-terminal telopeptide of type I collagen (ICTP) in serum-in 63 healthy postmenopausal women and 63 women with osteoporosis characterized by more bone resorption than bone formation. The ICTP, PYR and DPR levels were all higher, by 24% (p = 0.001), 16% (p = 0.05) and 25% (p = 0.004), respectively, in the osteoporotic women. For the merged groups, there were significant correlations between serum ICTP concentration and urinary PYR (r = 0.667, p < 0.0001) and DPR (r = 0.452, p < 0.0001) excretion; for the osteoporotic and normal women separately, the r values were 0.73 (p < 0.01) and 0.45 (p < 0.01) for PYR and 0.51 (p < 0.01) and 0.22 (p = 0.08) for DPR versus ICTP respectively. Weak correlations in linear regression between ICTP and various indices of bone formation (osteocalcin, bone-specific alkaline phosphatase and carboxy-terminal propeptide of type I procollagen) disappeared when the correlation between ICTP and pyridinolines was accounted for by calculation of partial correlation coefficients in multiple regression analysis. Serum ICTP concentration appears to discriminate between groups of normal and osteoporotic women as well as urinary pyridinium cross-links, which is thus far the most sensitive method for assessing bone resorption.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7921210     DOI: 10.1530/eje.0.1310258

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  Nocturnal rise in markers of bone resorption is not abolished by bedtime calcium or calcitonin.

Authors:  S Sairanen; R Tähtelä; K Laitinen; S L Karonen; M J Välimäki
Journal:  Calcif Tissue Int       Date:  1994-11       Impact factor: 4.333

2.  PLCL1 rs7595412 variation is not associated with hip bone size variation in postmenopausal Danish women.

Authors:  Stéphane Cauchi; Inger Byrjalsen; Emmanuelle Durand; Morten A Karsdal; Philippe Froguel
Journal:  BMC Med Genet       Date:  2009-12-23       Impact factor: 2.103

3.  Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.

Authors:  C Blomqvist; L Risteli; J Risteli; P Virkkunen; S Sarna; I Elomaa
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

4.  Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients.

Authors:  T Saarto; C Blomqvist; J Risteli; L Risteli; S Sarna; I Elomaa
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

5.  Repeated vertebral augmentation for new vertebral compression fractures of postvertebral augmentation patients: a nationwide cohort study--how useful is the current clinical gold standard for fracture risk?

Authors:  Hannah C P Wilson; Paul D Abel; S Imran A Shah
Journal:  Clin Interv Aging       Date:  2015-10-19       Impact factor: 4.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.